Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.
Valneva's vision is to contribute to a world where no one dies or suffers from a vaccine-preventable disease. Valneva aims to become the leading vaccine biotech company by complementing product sales growth with the development of high value R&D assets.
Valneva's mission is to help protect the lives of people around the world through the discovery, development, and commercialization of innovative vaccines against infectious diseases.
Valneva's commercial portfolio includes two vaccines for travelers:
+ IXIARO®/JESPECT®, indicated for the prevention of Japanese encephalitis; and
+ DUKORAL®, indicated for the prevention of cholera and, in some countries,
prevention of diarrhea caused by Enterotoxigenic escherichia coli.
Valneva invests proceeds from its commercial business in R&D. The Company's clinical pipeline includes a unique vaccine candidate against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada, and the US, with over 450 employees.